Filing Flows › Comparisons › ZOMDF vs INBP
Zomedica vs Integrated Biopharma: ZOMDF and INBP compared
Zomedica is the larger company: $9.9M of revenue in its latest quarter (Q3 2026) against $9.8M for Integrated Biopharma (Q4 FY26). Zomedica is growing faster (+22% against -31% a year earlier). Integrated Biopharma is more profitable, with an operating margin of -8.9% against -34.6%.
Where the money goes: ZOMDF and INBP
Zomedica (ZOMDF) · Q3 2026
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
Integrated Biopharma (INBP) · Q4 FY26
Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%, net loss $1.4M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Zomedica (ZOMDF) | Integrated Biopharma (INBP) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 FY26 |
| Revenue | $9.9M | $9.8M |
| Revenue growth, Y/Y | +22% | -31% |
| Operating margin | -34.6% | -8.9% |
| Net earnings | −$3.2M | −$1.4M |
| Net margin | -32.0% | -13.9% |
| Operating cash flow | −$2.8M | −$1.2M |
Where the revenue comes from
Zomedica
- Consumables: $6.8M (69%)
- Capital: $2.0M (20%)
- Engineering: $981K (10%)
- Other: $116K (1%)
Integrated Biopharma
- Contract Manufacturing: $9.5M (97%)
- Other Nutraceutical Business: $318K (3%)
Questions
Which is bigger, Zomedica or Integrated Biopharma?
Zomedica is the larger company: $9.9M of revenue in its latest quarter (Q3 2026) against $9.8M for Integrated Biopharma (Q4 FY26).
Is Zomedica or Integrated Biopharma growing faster?
Zomedica is growing faster (+22% against -31% a year earlier).
Which is more profitable, Zomedica or Integrated Biopharma?
Integrated Biopharma is more profitable, with an operating margin of -8.9% against -34.6%.
More: Zomedica earnings · how Zomedica makes money · Integrated Biopharma earnings · how Integrated Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-K filed Sep 25, 2026). Fiscal quarters can end on different dates. Not investment advice.